This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by van der Post, J. P. Articles by van Gerven, J. M. A. Search for Related Content PubMed PubMed Citation Articles by van der Post, J. P. Articles by van Gerven, J. M. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Social Bookmarking                         What's this?

Pharmacokinetic/pharmacodynamic Assessment of Tolerance to Central Nervous System Effects of a 3 mg Sustained Release Tablet of Rilmenidine in Hypertensive Patients

Centre for Human Drug Research, Leiden, The Netherlands., jvdp{at}chdr.nl

S. J. de Visser

Centre for Human Drug Research, Leiden, The Netherlands.

R. C. Schoemaker

Centre for Human Drug Research, Leiden, The Netherlands.

A. F. Cohen

Centre for Human Drug Research, Leiden, The Netherlands.

J. M. A. van Gerven

Centre for Human Drug Research, Leiden, The Netherlands.

Previous single-dose studies have shown clear blood pressure-lowering effects of a potential sustained release (SR) profile of rilmenidine, with concentration-dependent effects on the central nervous system. The aim of this study was to evaluate potential changes in concentration-effect-relationships for these central nervous system effects during a 4-week treatment period with an experimental SR formulation of rilmenidine 3 mg once daily in 15 mild-to-moderate hypertensive patients. The central nervous system effects of the treatment were evaluated using saccadic eye movements for sedative effects and visual analogue scales for subjective effects on alertness, mood and calmness. Measurements for pharmacokinetic and pharmacodynamic evaluations were performed on the first day of the treatment period and repeated after 1 week and 4 weeks of treatment. Drug concentrations increased during the study, whereas treatment related reductions in saccadic peak velocity (SPV) remained similar on all three study days. The slopes of the concentration-effect-curves for SPV remained unchanged throughout the study, while the intercepts tended to increase as a result of increased pre-dose values. Similar effects were observed for visual analogue scales for alertness: pre-dose values increased significantly during the study, while the size of the treatment responses (slopes) remained unaltered. The reasons for these adaptations cannot be determined but may include drug tolerance and habituations to study procedures. Blood pressure control remained stable and adequate throughout the study.

Key Words: eye movements • hypertension • imidazoline • PK-PD • sedation • visual analogue scales

Journal of Psychopharmacology, Vol. 18, No. 2, 221-227 (2004)
DOI: 10.1177/0269881104042626


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Strougo, L. Zuurman, C. Roy, J. Pinquier, J. van Gerven, A. Cohen, and R. Schoemaker Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids J Psychopharmacol, September 1, 2008; 22(7): 717 - 726. [Abstract] [PDF]